Overview

Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)

Status:
Completed

Trial end date:
2021-10-25

Target enrollment:

Participant gender:

Summary

The purpose of the study is to determine if a high dose of IVIG plus SMT can reduce all-cause mortality versus SMT alone in hospitalized participants with COVID-19 requiring admission to the ICU through Day 29.

Phase:

Phase 2

Details

Lead Sponsor:

Grifols Therapeutics LLC

Treatments:

Immunoglobulins, Intravenous